Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik (IGB)
About Fraunhofer-Institut IGB
The Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB develops solutions for industry and public clients in the fields of health, environment and technology. Our areas of expertise include interfacial engineering, membrane technology, biotechnology and cell systems technology as well as bioprocess technology. We offer our customers complete solutions from market analysis and research through to application-ready development.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Employees : 10,001+
- Industry : Production technology
News about Fraunhofer-Institut IGB
Here you will find Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik (IGB)
Last viewed contents
Synthesizing fine chemicals: Technological Advance in Production of Pharmaceuticals
Obesity: Genetic predisposition as cause, drugs from diabetes therapy help
Researchers combine light and X-ray microscopy for comprehensive insights
Artificial photosynthesis for environmentally friendly food production - Researchers produce important amino acid from greenhouse gas CO₂
Start-ups in Europe: Significant Potential Remains Untapped - Study Shows Differences Between Start-ups in France, Germany and the United Kingdom
Antimicrobial peptides can reduce salmonella in chickens - This discovery could help improve food safety and protect public health without relying on antibiotic use
Corden Pharma International GmbH - Plankstadt, Germany
Novel virtual trade fair for the process industry - A new way to network and stay informed defies postponed or cancelled trade fairs: The "virtual process show" from 8 to 11 September 2020
Bio-concrete from urine - Feasibility study: How to transform urine into a sustainable building material
A sweet defence against lethal bacteria - Synthesising a potential vaccine candidate for an antibiotic-resistant pathogen causing infections in hospitalised patients
Bayer Group: First-quarter performance as expected - “We’re consolidating roles, designing teams for more impact, and taking out layers”
